Alnylam Pharmaceuticals on Lawsuits Case Study Essay
Order ID:89JHGSJE83839 Style:APA/MLA/Harvard/Chicago Pages:5-10 Instructions:
Alnylam Pharmaceuticals on Lawsuits Case Study Essay
Student learning outcome(s) for the course include demonstrating an understanding of compliance standards required to formulate regulatory
strategies to support effective life-cycle management. Intellectual property strategy is a critical area of product life-cycle management in
healthcare, as well as many other sectors of the global economy, but is often overlooked for a variety of reasons. The Alnylam Pharmaceuticals
Case Study describes a commercialization scenario in which Alnylam has filed a lawsuit against the co-owners of a patent pending application. In
addition, to addressing the validity of patent(s) pending, the case illustrates the importance of the outcome of the aforementioned litigation on the
Company’s corporate strategy. As with the previous case write-up assignments the questions for this Case Study write-up require you to explain
critical aspects of the case from a situational perspective, as well as to develop replies to specific questions presented by the case.
Questions
- In 2-3 paragraphs please present a situational description of the case that addresses: Who is Dr. John Marginate? Who are the stakeholders involved in the case and what are their roles? Why are they working (or not working) together collaboratively?
- How do you balance the risks vs. rewards of Alnylam’s licensing strategy? What are its pros and cons? How should Alnylam sustain its IP and licensing strategy? Should Alnylam Pharmaceuticals convert its business model such that it becomes an intellectual property licensing company?
- Are there specific aspects about RNA interference as a technology platform that make it easier or harder to develop and subsequently execute an intellectual property strategy to protect it?
- Why are the co-owners of the Toschi I patent arguing over the patent’s prosecution?
- If Merck, through Sarna, has a license to Toschi I, should it also need a license from Alnylam?
- At what point, if ever, should Alnylam negotiate with Merck for a license to the latter’s intellectual property
5-7 pages in length, single or double-spaced in 12 pt. font
Alnylam Pharmaceuticals on Lawsuits Case Study Essay
RUBRIC
Excellent Quality
95-100%
Introduction 45-41 points
The background and significance of the problem and a clear statement of the research purpose is provided. The search history is mentioned.
Literature Support
91-84 points
The background and significance of the problem and a clear statement of the research purpose is provided. The search history is mentioned.
Methodology
58-53 points
Content is well-organized with headings for each slide and bulleted lists to group related material as needed. Use of font, color, graphics, effects, etc. to enhance readability and presentation content is excellent. Length requirements of 10 slides/pages or less is met.
Average Score
50-85%
40-38 points
More depth/detail for the background and significance is needed, or the research detail is not clear. No search history information is provided.
83-76 points
Review of relevant theoretical literature is evident, but there is little integration of studies into concepts related to problem. Review is partially focused and organized. Supporting and opposing research are included. Summary of information presented is included. Conclusion may not contain a biblical integration.
52-49 points
Content is somewhat organized, but no structure is apparent. The use of font, color, graphics, effects, etc. is occasionally detracting to the presentation content. Length requirements may not be met.
Poor Quality
0-45%
37-1 points
The background and/or significance are missing. No search history information is provided.
75-1 points
Review of relevant theoretical literature is evident, but there is no integration of studies into concepts related to problem. Review is partially focused and organized. Supporting and opposing research are not included in the summary of information presented. Conclusion does not contain a biblical integration.
48-1 points
There is no clear or logical organizational structure. No logical sequence is apparent. The use of font, color, graphics, effects etc. is often detracting to the presentation content. Length requirements may not be met
You Can Also Place the Order at www.collegepaper.us/orders/ordernow or www.crucialessay.com/orders/ordernow
Alnylam Pharmaceuticals on Lawsuits Case Study Essay